1. Home
  2. TFX vs IMVT Comparison

TFX vs IMVT Comparison

Compare TFX & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Teleflex Incorporated

TFX

Teleflex Incorporated

HOLD

Current Price

$120.00

Market Cap

4.6B

Sector

Health Care

ML Signal

HOLD

Logo Immunovant Inc.

IMVT

Immunovant Inc.

HOLD

Current Price

$25.63

Market Cap

5.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TFX
IMVT
Founded
1943
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.6B
5.0B
IPO Year
1994
2019

Fundamental Metrics

Financial Performance
Metric
TFX
IMVT
Price
$120.00
$25.63
Analyst Decision
Buy
Buy
Analyst Count
9
9
Target Price
$138.75
$30.78
AVG Volume (30 Days)
652.4K
1.1M
Earning Date
04-30-2026
05-28-2026
Dividend Yield
1.14%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,992,713,000.00
N/A
Revenue This Year
$15.97
N/A
Revenue Next Year
$5.15
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$100.18
$13.36
52 Week High
$138.93
$29.25

Technical Indicators

Market Signals
Indicator
TFX
IMVT
Relative Strength Index (RSI) 63.79 53.96
Support Level $117.09 $24.63
Resistance Level $123.74 $27.71
Average True Range (ATR) 3.28 1.25
MACD 0.93 0.17
Stochastic Oscillator 99.44 92.36

Price Performance

Historical Comparison
TFX
IMVT

About TFX Teleflex Incorporated

Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.

About IMVT Immunovant Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.

Share on Social Networks: